News Targeting Tau to keep neurons connected 19/01/2021 An international team of researchers led by Patrik Verstreken at VIB-KU Leuven has succeeded in reversing the effects of Tau, a protein implicated in over 20 different diseases, including Alzheimer’s disease. Brain enzyme caught in the act 18/12/2020 Researchers from the lab of Wim Versées (VIB-VUB) in collaboration with the team of Patrik Verstreken (VIB-KU Leuven) presents the three-dimensional structure of an enzyme involved in Parkinson’s disease, epilepsy, Alzheimer's disease, and Down syndrome. Three VIB group leaders receive an ERC Proof of Concept grant 28/07/2020 Each year, the European Research Council awards Proof of Concept grants to ERC grant holders who wish to take their ERC research one step further towards application. This year, no less than three VIB principal investigators have received an ERC PoC grant: Prof. Kevin Verstrepen (VIB-KU Leuven Center for Microbiology), Prof. Patrik Verstreken, and Prof. Stein Aerts (both from the VIB-KU Leuven Center for Brain and Disease Research). Belgian team secures million-dollar funding from Chan Zuckerberg Initiative 05/12/2018 Today, the Chan Zuckerberg Initiative (CZI), the philanthropic endeavor led by Facebook’s Mark Zuckerberg and his partner Priscilla Chan, announced the launch of its Neurodegeneration Challenge Network. This new network brings together experimental scientists from diverse biomedical research fields, as well as computational biologists and physicians, to understand the underlying causes of neurodegenerative disorders. Hsp90: more than just a chaperone 06/09/2018 Researchers from the Verstreken lab (VIB-KU Leuven) have identified a completely novel function for Hsp90, one of the most common and most studied proteins in our body. In addition to its well-known role as a protein chaperone, Hsp90 stimulates exosome release. These findings shed new light on treatment strategies for both cancer and neurodegenerative diseases. Sleep problems in Parkinson’s disease: can we fix them? 07/06/2018 A team of researchers at VIB and KU Leuven has uncovered why people with a hereditary form of Parkinson’s disease suffer from sleep disturbances. The molecular mechanisms uncovered in fruit flies and human stem cells also point to candidate targets for the development of new treatments. VIB scientists Jenny Russinova and Patrik Verstreken elected as EMBO Members 15/05/2018 EMBO elected 62 outstanding life scientists to its membership, joining a group of more than 1800 of the best researchers in Europe and around the world. Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration 01/02/2018 Tau proteins clump together to form neuronal tangles, found in patient brains of more than twenty different neurodegenerative diseases, including various forms of dementia. Last year, researchers at VIB and KU Leuven uncovered that Tau disturbs neuronal communication when it is mislocalized to presynaptic terminals during early disease stages. In a new study, the researchers report that a protein called Synaptogyrin-3 is mediating these effects and could be a new potential target for therapeutic development. Tau prevents synaptic transmission at early stage of neurodegeneration 19/05/2017 Tau proteins are involved in more than twenty neurodegenerative diseases, including various forms of dementia. These proteins clump together in patients’ brains to form neuronal tangles: protein aggregation that eventually coincides with the death of brain cells. Prof. Patrik Verstreken’s research team (VIB-KU Leuven) has now discovered how tau disrupts the functioning of nerve cells, even before it starts forming tangles. They immediately suggest a way to intervene in this process. 200 years of Parkinson's research 29/03/2017 2017 marks the 200th anniversary of James Parkinson’s description of the disease that now bears his name and that affects an estimated 5 million people worldwide. Working as a medical surgeon in London, James Parkinson was the first to connect the dots when confronted with a handful of patients with similar involuntary tremors and symptoms of muscle weakness. In 1817, he published his findings in his seminal ‘Essay on shaking palsy’. Pagination Current page 1 Page 2 Next page Next ›
Targeting Tau to keep neurons connected 19/01/2021 An international team of researchers led by Patrik Verstreken at VIB-KU Leuven has succeeded in reversing the effects of Tau, a protein implicated in over 20 different diseases, including Alzheimer’s disease.
Brain enzyme caught in the act 18/12/2020 Researchers from the lab of Wim Versées (VIB-VUB) in collaboration with the team of Patrik Verstreken (VIB-KU Leuven) presents the three-dimensional structure of an enzyme involved in Parkinson’s disease, epilepsy, Alzheimer's disease, and Down syndrome.
Three VIB group leaders receive an ERC Proof of Concept grant 28/07/2020 Each year, the European Research Council awards Proof of Concept grants to ERC grant holders who wish to take their ERC research one step further towards application. This year, no less than three VIB principal investigators have received an ERC PoC grant: Prof. Kevin Verstrepen (VIB-KU Leuven Center for Microbiology), Prof. Patrik Verstreken, and Prof. Stein Aerts (both from the VIB-KU Leuven Center for Brain and Disease Research).
Belgian team secures million-dollar funding from Chan Zuckerberg Initiative 05/12/2018 Today, the Chan Zuckerberg Initiative (CZI), the philanthropic endeavor led by Facebook’s Mark Zuckerberg and his partner Priscilla Chan, announced the launch of its Neurodegeneration Challenge Network. This new network brings together experimental scientists from diverse biomedical research fields, as well as computational biologists and physicians, to understand the underlying causes of neurodegenerative disorders.
Hsp90: more than just a chaperone 06/09/2018 Researchers from the Verstreken lab (VIB-KU Leuven) have identified a completely novel function for Hsp90, one of the most common and most studied proteins in our body. In addition to its well-known role as a protein chaperone, Hsp90 stimulates exosome release. These findings shed new light on treatment strategies for both cancer and neurodegenerative diseases.
Sleep problems in Parkinson’s disease: can we fix them? 07/06/2018 A team of researchers at VIB and KU Leuven has uncovered why people with a hereditary form of Parkinson’s disease suffer from sleep disturbances. The molecular mechanisms uncovered in fruit flies and human stem cells also point to candidate targets for the development of new treatments.
VIB scientists Jenny Russinova and Patrik Verstreken elected as EMBO Members 15/05/2018 EMBO elected 62 outstanding life scientists to its membership, joining a group of more than 1800 of the best researchers in Europe and around the world.
Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration 01/02/2018 Tau proteins clump together to form neuronal tangles, found in patient brains of more than twenty different neurodegenerative diseases, including various forms of dementia. Last year, researchers at VIB and KU Leuven uncovered that Tau disturbs neuronal communication when it is mislocalized to presynaptic terminals during early disease stages. In a new study, the researchers report that a protein called Synaptogyrin-3 is mediating these effects and could be a new potential target for therapeutic development.
Tau prevents synaptic transmission at early stage of neurodegeneration 19/05/2017 Tau proteins are involved in more than twenty neurodegenerative diseases, including various forms of dementia. These proteins clump together in patients’ brains to form neuronal tangles: protein aggregation that eventually coincides with the death of brain cells. Prof. Patrik Verstreken’s research team (VIB-KU Leuven) has now discovered how tau disrupts the functioning of nerve cells, even before it starts forming tangles. They immediately suggest a way to intervene in this process.
200 years of Parkinson's research 29/03/2017 2017 marks the 200th anniversary of James Parkinson’s description of the disease that now bears his name and that affects an estimated 5 million people worldwide. Working as a medical surgeon in London, James Parkinson was the first to connect the dots when confronted with a handful of patients with similar involuntary tremors and symptoms of muscle weakness. In 1817, he published his findings in his seminal ‘Essay on shaking palsy’.
